Literature DB >> 28536264

Exosomes from uninfected cells activate transcription of latent HIV-1.

Robert A Barclay1, Angela Schwab1, Catherine DeMarino1, Yao Akpamagbo1, Benjamin Lepene2, Seble Kassaye3, Sergey Iordanskiy1,4, Fatah Kashanchi5.   

Abstract

HIV-1 infection causes AIDS, infecting millions worldwide. The virus can persist in a state of chronic infection due to its ability to become latent. We have previously shown a link between HIV-1 infection and exosome production. Specifically, we have reported that exosomes transport viral proteins and RNA from infected cells to neighboring uninfected cells. These viral products could then elicit an innate immune response, leading to activation of the Toll-like receptor and NF-κB pathways. In this study, we asked whether exosomes from uninfected cells could activate latent HIV-1 in infected cells. We observed that irrespective of combination antiretroviral therapy, both short- and long-length viral transcripts were increased in wild-type HIV-1-infected cells exposed to purified exosomes from uninfected cells. A search for a possible mechanism for this finding revealed that the exosomes increase RNA polymerase II loading onto the HIV-1 promoter in the infected cells. These viral transcripts, which include trans-activation response (TAR) RNA and a novel RNA that we termed TAR-gag, can then be packaged into exosomes and potentially be exported to neighboring uninfected cells, leading to increased cellular activation. To better decipher the exosome release pathways involved, we used siRNA to suppress expression of ESCRT (endosomal sorting complex required for transport) proteins and found that ESCRT II and IV significantly control exosome release. Collectively, these results imply that exosomes from uninfected cells activate latent HIV-1 in infected cells and that true transcriptional latency may not be possible in vivo, especially in the presence of combination antiretroviral therapy.

Entities:  

Keywords:  T-cell; endosomal sorting complexes required for transport (ESCRT); exosome (vesicle); human immunodeficiency virus (HIV); latency; monocyte; small interfering RNA (siRNA); transcription

Mesh:

Substances:

Year:  2017        PMID: 28536264      PMCID: PMC5512065          DOI: 10.1074/jbc.M117.793521

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  76 in total

1.  Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo.

Authors:  J A Mikovits; N C Lohrey; R Schulof; J Courtless; F W Ruscetti
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

2.  BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors:  Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal:  J Leukoc Biol       Date:  2012-07-16       Impact factor: 4.962

Review 3.  Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?

Authors:  Thomas A Rasmussen; Sharon R Lewin
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

4.  T-cell-induced expression of human immunodeficiency virus in macrophages.

Authors:  R D Schrier; J A McCutchan; J C Venable; J A Nelson; C A Wiley
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

5.  Sequence-specific interaction between HIV-1 matrix protein and viral genomic RNA revealed by in vitro genetic selection.

Authors:  P Purohit; S Dupont; M Stevenson; M R Green
Journal:  RNA       Date:  2001-04       Impact factor: 4.942

6.  Human T-lymphotropic virus type 1-infected cells secrete exosomes that contain Tax protein.

Authors:  Elizabeth Jaworski; Aarthi Narayanan; Rachel Van Duyne; Shabana Shabbeer-Meyering; Sergey Iordanskiy; Mohammed Saifuddin; Ravi Das; Philippe V Afonso; Gavin C Sampey; Myung Chung; Anastas Popratiloff; Bindesh Shrestha; Mohit Sehgal; Pooja Jain; Akos Vertes; Renaud Mahieux; Fatah Kashanchi
Journal:  J Biol Chem       Date:  2014-06-17       Impact factor: 5.157

7.  Association of hepatitis C virus envelope proteins with exosomes.

Authors:  Francesca Masciopinto; Cinzia Giovani; Susanna Campagnoli; Luisa Galli-Stampino; Piero Colombatto; Maurizia Brunetto; T S Benedict Yen; Michael Houghton; Piero Pileri; Sergio Abrignani
Journal:  Eur J Immunol       Date:  2004-10       Impact factor: 5.532

Review 8.  Recent advances in dynamic m6A RNA modification.

Authors:  Guangchao Cao; Hua-Bing Li; Zhinan Yin; Richard A Flavell
Journal:  Open Biol       Date:  2016-04-13       Impact factor: 6.411

Review 9.  Exosome function: from tumor immunology to pathogen biology.

Authors:  Jeffrey S Schorey; Sanchita Bhatnagar
Journal:  Traffic       Date:  2008-03-06       Impact factor: 6.215

10.  Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.

Authors:  E Verdin; P Paras; C Van Lint
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

View more
  43 in total

1.  Specific packaging and circulation of cytochromes P450, especially 2E1 isozyme, in human plasma exosomes and their implications in cellular communications.

Authors:  Santosh Kumar; Namita Sinha; Kelli A Gerth; Mohammad A Rahman; Murali M Yallapu; Narasimha M Midde
Journal:  Biochem Biophys Res Commun       Date:  2017-07-26       Impact factor: 3.575

2.  LEDGINs, Inhibitors of the Interaction Between HIV-1 Integrase and LEDGF/p75, Are Potent Antivirals with a Potential to Cure HIV Infection.

Authors:  Zeger Debyser; Anne Bruggemans; Siska Van Belle; Julie Janssens; Frauke Christ
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Advances, challenges, and opportunities in extracellular RNA biology: insights from the NIH exRNA Strategic Workshop.

Authors:  Kang Li; Rodosthenis S Rodosthenous; Fatah Kashanchi; Thomas Gingeras; Stephen J Gould; Lillian S Kuo; Peter Kurre; Hakho Lee; Joshua N Leonard; Huiping Liu; Tania B Lombo; Stefan Momma; John P Nolan; Margaret J Ochocinska; D Michiel Pegtel; Yoel Sadovsky; Francisco Sánchez-Madrid; Kayla M Valdes; Kasey C Vickers; Alissa M Weaver; Kenneth W Witwer; Yong Zeng; Saumya Das; Robert L Raffai; T Kevin Howcroft
Journal:  JCI Insight       Date:  2018-04-05

Review 4.  Modern Techniques for the Isolation of Extracellular Vesicles and Viruses.

Authors:  Ryan P McNamara; Dirk P Dittmer
Journal:  J Neuroimmune Pharmacol       Date:  2019-09-12       Impact factor: 4.147

Review 5.  The Messenger Apps of the cell: Extracellular Vesicles as Regulatory Messengers of Microglial Function in the CNS.

Authors:  Adeyemi A Olanrewaju; Ramin M Hakami
Journal:  J Neuroimmune Pharmacol       Date:  2020-04-27       Impact factor: 4.147

6.  MicroRNAs and exosomes: key players in HIV pathogenesis.

Authors:  J Sadri Nahand; F Bokharaei-Salim; M Karimzadeh; M Moghoofei; S Karampoor; H R Mirzaei; A Tabibzadeh; A Jafari; A Ghaderi; Z Asemi; H Mirzaei; M R Hamblin
Journal:  HIV Med       Date:  2019-11-22       Impact factor: 3.180

Review 7.  Nano-based drug delivery system: a smart alternative towards eradication of viral sanctuaries in management of NeuroAIDS.

Authors:  Nidhi Aggarwal; Bushra Nabi; Sumit Aggarwal; Sanjula Baboota; Javed Ali
Journal:  Drug Deliv Transl Res       Date:  2021-01-23       Impact factor: 4.617

Review 8.  Epigenetic Mechanisms of HIV-1 Persistence.

Authors:  Roxane Verdikt; Olivier Hernalsteens; Carine Van Lint
Journal:  Vaccines (Basel)       Date:  2021-05-17

9.  Extracellular Vesicles as a Means of Viral Immune Evasion, CNS Invasion, and Glia-Induced Neurodegeneration.

Authors:  Miranda D Horn; Andrew G MacLean
Journal:  Front Cell Neurosci       Date:  2021-07-05       Impact factor: 5.505

10.  Plasma Extracellular Vesicles Enhance HIV-1 Infection of Activated CD4+ T Cells and Promote the Activation of Latently Infected J-Lat10.6 Cells via miR-139-5p Transfer.

Authors:  Isobel Okoye; Lai Xu; Olaide Oyegbami; Shima Shahbaz; Desmond Pink; Priscilla Gao; Xuejun Sun; Shokrollah Elahi
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.